Assembly Biosciences Inc. (ASMB)
ASMB trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1426800/000119312526115992/0001193125-26-115992-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | ASMB on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | 2010 |
| SEC CIK | 0001426800 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $72.3M |
| Net income | -$6.1M |
| Operating income | -$12.1M |
| Net margin | -8.5% |
| Operating margin | -16.8% |
| Revenue growth | +153.5% |
| Cash | $58.5M |
| Total assets | $257.6M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 6.0× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-12 |
| Cash and burn | $29.1M cash; operating cash flow -$10.1M a quarter. | Report 2026-09-30 |
| Shares outstanding | 20,477,244 (2026-11-06); 15,817,140 a year earlier; 65,709,112 three years earlier. 3y figure adjusted for splits (1-for-12 overall). | Cover page 2026-11-06 |
| Reverse splits, 3 years | 1; latest 1-for-12 on 2024-02-12 | Source 2024-02-12 |
| Shelf and offerings, 12 months | 1 S-3/F-3 shelf filings; 2 424B5 takedowns | Latest 2026-05-26 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Ernst & Young LLP, San Jose, California, United States | PCAOB Form AP 2026-04-06 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $15K on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $3.0M | -$20.3M | -$17.2M | $29.1M | No debt tags | Needs four quarters | 10-Q 2026-11-12 |
| Q2 2026 2026-06-30 | $13.4M | -$3.9M | -$15.5M | $32.3M | No debt tags | Needs four quarters | 10-Q 2026-08-13 |
| Q1 2026 2026-03-31 | $8.2M | -$9.1M | -$22.1M | $31.1M | No debt tags | Needs four quarters | 10-Q 2026-05-07 |
| Q4 2025 2025-12-31 | Not filed | $22.1M | $14.2M | $58.5M | No debt tags | $72.3M | 10-K 2026-03-19 |
| Q3 2025 2025-09-30 | $10.8M | -$9.2M | -$15.1M | $22.5M | No debt tags | $37.2M | 10-Q 2026-11-12 |
| Q2 2025 2025-06-30 | $9.6M | -$10.2M | -$16.8M | $24.0M | No debt tags | $33.2M | 10-Q 2026-08-13 |
| Q1 2025 2025-03-31 | $9.4M | -$8.8M | -$23.4M | $23.4M | No debt tags | $32.2M | 10-Q 2026-05-07 |
| Q4 2024 2024-12-31 | $7.4M | -$10.3M | -$407K | $38.3M | No debt tags | $28.5M | 10-K 2025-03-20 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2026-05-26 |
| Latest annual report | 10-K | 2026-03-19 |
| Latest quarterly / interim | 10-Q | 2026-11-12 |
| Latest current report | 8-K | 2026-11-12 |
| Latest proxy | DEFA14A | 2026-04-22 |
Source: SEC EDGAR submissions feed, 904 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +3.4% |
| 1 month | +3.8% |
| 3 months | -29.5% |
| Year to date | -37.9% |
| 1 year | -40.5% |
| From 52-week high | -45.1% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| BLSM | BlossomHill Therapeutics Inc. | $13.65 | -2.64% | $433.9M |
| EOLS | Evolus Inc. | $6.63 | -4.74% | $438.8M |
| CTMX | CytomX Therapeutics Inc. | $1.99 | -2.70% | $432.7M |
| ARVN | Arvinas Inc. | $6.77 | -0.73% | $443.3M |
| AVTX | Avalo Therapeutics Inc. | $7.37 | -5.03% | $426.2M |
| MPLT | MapLight Therapeutics Inc. | $6.90 | -4.83% | $446.9M |
| DMAC | DiaMedica Therapeutics Inc. | $8.33 | -5.23% | $449.5M |
| OVID | Ovid Therapeutics Inc. | $2.40 | -5.51% | $453.0M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier